Core Viewpoint - The Oncology Institute, Inc. (TOI) will announce its first quarter 2025 financial results on May 14, 2025, after market close, followed by a conference call at 5:00 p.m. Eastern Time [1]. Group 1: Financial Results Announcement - TOI is set to release its Q1 2025 financial results on May 14, 2025, after the market closes [1]. - A conference call will take place on the same day at 5:00 p.m. Eastern Time to discuss the results [1]. Group 2: Conference Call Access - The conference call can be accessed by dialing 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2]. - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13752832 [2]. - The replay will be available until May 21, 2025 [2]. Group 3: Webcast Information - Interested parties can also listen to a simultaneous webcast of the conference call via the Investor Relations section of TOI's website [3]. Group 4: Company Overview - Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients with advanced oncology services [4]. - The company employs over 120 clinicians and has more than 700 staff across over 70 clinic locations [4].

Group 1 - Topicus.com Inc. plans to release its first quarter results on May 2, 2025 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on May 2, 2025 [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus focuses on acquiring, managing, and building vertical market software businesses [2]

CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents. The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategi ...

Patient Care and Services - In 2024, the company provided care for over 72,000 patients and managed a population of approximately 1.9 million patients under value-based agreements[24]. - The company operates 72 clinics across 16 markets in 5 states, employing 130 providers and contracting with 11 additional providers in independently-owned clinics[23]. - The company has developed a High Value Cancer Care program that aligns treatment regimens with National Comprehensive Cancer Network guidelines[45]. - The company operates specialty and retail pharmacies to fill medication orders related to oncology care, billing pharmacy benefit managers for these services[28]. - The average patient rating based on 3,500+ Google reviews is 4.6 out of 5 stars, indicating high patient satisfaction[51]. - The company employs a continuous feedback mechanism to ensure superior patient experience and satisfaction among affiliated providers[50]. - The company aims to provide top-quality oncology care and has implemented initiatives for talent acquisition, diversity, and employee engagement[95]. - The company’s ability to attract and retain patients is dependent on providing high-quality care, which is essential for maintaining its reputation and financial condition[160]. Financial Performance and Revenue - More than 46% of the company's revenue in 2024 was generated from patients covered by value-based contracts, primarily capitated contracts[33]. - More than 50% of the company's revenue in 2024 was generated from value-based contracts, with the largest customer representing approximately 16% of patient services revenue[64][65]. - The Patient Services revenue constituted about 52% of total revenue for the year ended December 31, 2024, highlighting the significance of this revenue stream[150]. - The company achieved over 25% lower median total healthcare costs from diagnosis to death[46]. - The company received approximately 16% of its Patient Services revenue directly from Medicare in 2024, emphasizing dependence on government reimbursement[132]. - About 17% of the company's revenue for 2024 was derived from fixed fees paid by payors under capitation agreements, highlighting reliance on value-based contracts[122]. - The company anticipates significant increases in operating expenses as it continues to hire additional personnel and expand its infrastructure[109]. - The company incurred a net loss of $64,663,000 in 2024, with expectations of continued losses due to heavy investments in expanding patient base and operations[108]. Market Opportunities and Growth Strategy - The company has a substantial opportunity to capture a portion of approximately 81 million commercial, Medicaid, and Medicare Advantage lives across its active states[40]. - The company plans to leverage existing payor relationships to enter new markets, focusing on Medicare Advantage and value-based reimbursement models[58]. - The company anticipates significant growth potential in existing markets by expanding services with existing partners and securing new contracts[58]. - The company has a robust and data-driven approach to acquisitions, with a strong pipeline of targets in both existing and new markets[67]. - The growth strategy relies on building or acquiring new TOI PC clinics, which is dependent on various factors including obtaining referrals and entering contracts with additional payors[102]. Regulatory and Compliance Risks - The company is subject to various federal and state laws governing the collection and protection of personal information, including health-related data[89]. - The company is subject to extensive fraud, waste, and abuse laws, which may lead to audits and investigations that could adversely affect operations[103]. - The company is subject to audits by payors, including governmental audits of Medicare claims, which may require repayment if incorrect reimbursements are identified[119]. - The operations of the managed clinics are subject to extensive federal, state, and local regulations, which include compliance with Medicare and Medicaid programs[196]. - Changes in healthcare laws and regulations, including those affecting telehealth, could adversely impact the company's financial condition and operational results[121]. - The company faces rising enforcement actions for noncompliance with privacy and data protection laws, which are complex and rapidly evolving[198]. Competition and Market Challenges - The company faces competition for payor relationships with other healthcare organizations, which may increase costs and impact revenue[110]. - The company faces competition from other oncology providers, which could hinder its ability to attract new patients and payors, impacting revenue growth[118]. - A pandemic or outbreak of infectious disease could significantly impact the company's operations and financial condition, with potential delays in patient care and increased costs[112]. - The transition from volume to value-based reimbursement models may adversely affect operations and financial results[1]. Operational and Financial Management - The company has experienced rapid growth and organizational change, which has placed significant demands on management and resources[106]. - The company may pursue acquisitions of oncology and other physician practices, which could involve significant cash expenditures and operational losses[173]. - The company may need additional capital to fund operations and finance growth, which may not be obtainable on acceptable terms, potentially limiting growth strategies[219]. - The company is substantially dependent on a single source of drug supplies, which poses risks if the supplier fails to meet needs or if there are material price increases[162]. - The company’s information technology strategy is critical for maintaining effective operations and meeting regulatory demands, with potential compliance challenges if not properly managed[164]. Tax and Financial Reporting - As of December 31, 2024, the company had federal income tax NOLs of $184,835,785 and state income tax NOLs of $175,187,277 available to offset future taxable income[209]. - The deferred tax asset associated with the company's NOLs is fully offset by a valuation allowance, meaning future changes in unrecognized tax benefits will not impact the effective tax rate[209]. - Future changes in tax laws and regulations could adversely affect the company's business, financial condition, and results of operations[210]. - The company may face additional tax liabilities due to audits by taxing authorities, which could materially affect its financial condition and results of operations[213]. Legal and Liability Risks - Legal proceedings and litigation could materially harm the company’s business and results of operations, with significant costs associated with defending against such claims[167]. - Medical liability claims against TCR and TOI PCs could result in substantial damage awards, impacting financial condition and increasing insurance costs[184]. - Changes in accounting standards by FASB could adversely affect the consolidation of total revenues derived from TOI PCs, impacting financial reporting[186]. Cybersecurity and Data Protection - Cybersecurity risks remain a concern, as breaches could lead to significant reputational and financial harm[165]. - The Federal Trade Commission expects reasonable data security measures, and failure to comply may result in claims of unfair or deceptive practices[204].

The Oncology Institute, Inc. (NASDAQ:TOI) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Conference Call Participants Yuan Zhi - B. Riley Robert LeBoyer - NOBLE Capital Markets Mark Hueppelsheuser Good afternoon, and welcome to The Oncology Institute, Inc.'s Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks ...

Financial Performance - Consolidated revenue for Q4 2024 was $100 million, an increase of 16.9% compared to Q4 2023[8] - Consolidated revenue for the year ended December 31, 2024 was $393 million, an increase of 21.3% compared to the prior year[13] - Total operating revenue for Q4 2024 was $100,267,000, an increase of 16.8% compared to $85,788,000 in Q4 2023[43] - Total operating revenue for the year ended December 31, 2024 was $393,412,000, a 21.4% increase from $324,239,000 in 2023[43] - For the fiscal year 2025, the company expects revenue between $460 million and $480 million[7] Cash Flow and Assets - Cash flow from operations in Q4 2024 was approximately $4.2 million, driven by disciplined working capital management[5] - Cash and cash equivalents increased to $49,669 in 2024 from $33,488 in 2023, marking a growth of 48.4%[42] - Cash and cash equivalents at the end of Q4 2024 were $49,669,000, compared to $33,488,000 at the end of Q4 2023, reflecting an increase of 48.3%[44] - The company reported a net cash provided by operating activities of $4,186,000 in Q4 2024, compared to cash used of $3,882,000 in Q4 2023[44] Expenses and Losses - Selling, general, and administrative expenses decreased 12% in Q4 2024 compared to the prior year period, totaling $25 million[5] - Adjusted EBITDA for Q4 2024 was $(7.8) million, a decrease of $1.6 million compared to Q4 2023[12] - Net loss for Q4 2024 was $13.2 million, a decrease of $5.6 million compared to Q4 2023[12] - Net loss for the three months ended December 31, 2024, was $13,182, a decrease of 29.7% from a net loss of $18,754 in 2023[29] - Adjusted EBITDA for the year ended December 31, 2024, was $(35,688), representing a decline of 38.3% compared to $(25,805) in 2023[35] - Operating expenses totaled $112,196,000 in Q4 2024, up from $101,076,000 in Q4 2023, an increase of 11.1%[43] Revenue Sources - Dispensary revenue increased 72.4% compared to Q4 2023, attributed to an increase in filled prescriptions and average revenue per prescription[9] - Dispensary revenue increased significantly to $47,587,000 in Q4 2024 from $27,607,000 in Q4 2023, representing a growth of 72.2%[43] - Patient services revenue decreased to $50,217,000 in Q4 2024 from $56,171,000 in Q4 2023, a decline of 10.4%[43] Assets and Liabilities - Total current assets decreased to $112,418 as of December 31, 2024, down from $143,493 in 2023, reflecting a reduction of 21.6%[42] - The total liabilities increased to $169,128 in 2024 from $152,215 in 2023, an increase of 11.1%[42] - The accumulated deficit grew to $(210,813) in 2024 from $(146,150) in 2023, indicating a deterioration of 44.2%[42] Operational Growth - The number of clinics increased to 86 in 2024 from 83 in 2023, indicating a growth of 3.6%[41] - Lives under value-based contracts rose to 1.9 million in 2024, up from 1.8 million in 2023, representing a growth of 5.6%[41] - The company launched six new contracts in Q3 and Q4 2024, covering over 250,000 lives, with value-based patient services increasing sequentially by over 15%[5] Shareholder Information - The weighted-average number of shares outstanding increased to 75,655,231 in Q4 2024 from 73,469,101 in Q4 2023[43] - Share-based compensation decreased by 36.4% to $11,152 in 2024 from $17,548 in 2023[35] Impairment Charges - The company incurred goodwill impairment charges of $16,867,000 in 2023, which were not present in 2024[43]

Core Insights - The Oncology Institute, Inc. (TOI) reported a consolidated revenue of $100 million for Q4 2024, marking a 16.9% increase compared to Q4 2023, driven primarily by dispensary revenue growth [9][14] - The company achieved a net loss of $13.2 million in Q4 2024, an improvement from a net loss of $18.8 million in the same quarter of the previous year [13][18] - For the fiscal year 2025, TOI projects revenue between $460 million and $480 million, with gross profit expected to be between $73 million and $82 million [6] Recent Operational Highlights - TOI successfully reduced cash burn and generated positive cash flow from operations for the second consecutive quarter, amounting to approximately $4.2 million in Q4 2024 [4][7] - The company launched six new contracts in Q3 and Q4 2024, covering over 250,000 lives, contributing to a sequential increase of over 15% in value-based patient services [7][10] - A new agreement with the primary drug supplier improved discounts, optimizing cost positioning for revenue growth targets [7] Financial Performance - Q4 2024 gross profit was $15 million, a 1.8% increase from Q4 2023, while selling, general, and administrative expenses decreased by 12% year-over-year [11][12] - The total revenue for the year ended December 31, 2024, was $393 million, reflecting a 21.3% increase compared to the previous year [14] - Adjusted EBITDA for Q4 2024 was $(7.8) million, a decrease from $(6.3) million in Q4 2023, primarily due to changes in share-based compensation and fair value of derivative liabilities [13][19] Guidance and Outlook - The company anticipates Adjusted EBITDA of approximately $(5) to $(6) million for Q1 2025, influenced by seasonal factors such as drug price increases and lower encounter volumes [8] - TOI's outlook for 2025 assumes a largely reopened global market, with potential impacts from any reimplementation of restrictive measures [8] Key Business Metrics - As of December 31, 2024, TOI operated 86 clinics and served approximately 1.9 million patients under value-based contracts [41] - The company reported cash, cash equivalents, and investments totaling $50 million as of December 31, 2024 [7]

Core Viewpoint - The Oncology Institute, Inc. (TOI) has announced a private placement expected to generate approximately $16.5 million in gross proceeds, aimed at supporting organic growth and working capital needs [1][5]. Group 1: Private Placement Details - The private placement involves accredited investors and includes participation from existing investors and members of the management team and Board of Directors [1]. - Each unit in the private placement consists of two shares of common stock (or pre-funded warrants) and common warrants to purchase one share of common stock at a price of $2.2084 per unit [2]. - The pre-funded warrants will have an exercise price of $0.0001 per share, while the common warrants will have an exercise price of $1.1980 per share [2]. Group 2: Exchange Agreement - Deerfield Management Company has agreed to exchange approximately $4.1 million of the Company's senior secured convertible notes for 37,232.83 shares of common-equivalent preferred stock and warrants to purchase 1,861,642 shares of common stock at the same prices as the private placement [4]. Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to support organic growth and working capital needs [5]. Group 4: Company Overview - Founded in 2007, TOI is one of the largest value-based community oncology groups in the U.S., providing specialized cancer care to over 1.8 million patients [8]. - The organization employs over 120 clinicians and has more than 700 team members across over 70 clinic locations [8].

Core Viewpoint - The Oncology Institute, Inc. (TOI) will announce its fourth quarter and full year 2024 financial results on March 25, 2025, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - TOI will release its financial results after market close on March 25, 2025 [1]. - A conference call will take place on the same day at 5:00 p.m. Eastern Time [1]. Group 2: Conference Call Access - The conference call can be accessed by phone at 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2]. - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13750791 [2]. - The replay will be available until April 1, 2025 [2]. Group 3: Company Overview - Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients [4]. - The company employs over 120 clinicians and has more than 700 teammates across over 70 clinic locations [4]. - TOI provides advanced cancer care services, including clinical trials and transfusions, aiming to improve oncology care delivery [4].

Core Insights - Topicus.com Inc. reported strong financial results for Q4 and the full year 2024, with total revenue reaching €364.9 million for the quarter and €1,294.9 million for the year, marking increases of 18% and 15% respectively compared to 2023 [5][8] - The company's net income for Q4 2024 was €56.2 million, a 32% increase from €42.5 million in Q4 2023, while the annual net income rose to €149.5 million, up 30% from €115.4 million in 2023 [6][8] - Cash flows from operations (CFO) also saw significant growth, increasing by 28% to €79.6 million in Q4 and by 41% to €347.6 million for the full year [7][8] Financial Performance - Total revenue for Q4 2024 was €364.9 million, up from €309.7 million in Q4 2023, driven by acquisitions and organic growth of 5% [5][8] - For the full year 2024, total revenues were €1,294.9 million, compared to €1,125.0 million in 2023, with organic growth also at 5% [5][8] - Net income for Q4 2024 was €56.2 million, translating to €0.40 per share, compared to €42.5 million (€0.31 per share) in Q4 2023 [6][8] - Annual net income increased to €149.5 million (€1.11 per share) from €115.4 million (€0.88 per share) in 2023 [6][8] Cash Flow and Acquisitions - CFO for Q4 2024 increased to €79.6 million from €62.4 million in Q4 2023, representing a 28% growth [7][8] - For the full year, CFO rose to €347.6 million from €246.6 million, a 41% increase [7][8] - Free cash flow available to shareholders (FCFA2S) for Q4 2024 was €36.6 million, up 27% from €28.9 million in Q4 2023, and for the full year, it increased to €177.4 million from €123.4 million, a 44% rise [9][8] - The company completed acquisitions for a total cash consideration of €153.4 million in 2024, including holdbacks and contingent considerations [8] Balance Sheet Highlights - As of December 31, 2024, total assets were €1,535.9 million, up from €1,432.8 million in 2023 [15][16] - Current assets included cash of €206.2 million and accounts receivable of €142.8 million [15] - Total liabilities increased to €1,004.5 million from €840.3 million in 2023, with current liabilities including a revolving credit facility of €225.7 million [16] Shareholder Returns - The company paid dividends totaling €127.6 million to shareholders in 2024 [26] - Retained earnings as of December 31, 2024, were €266.3 million, down from €297.4 million in 2023 [21][23]